Back to Results
First PageMeta Content
Lysosomal storage diseases / Glycogen storage disease type II / Hepatology / Alglucosidase alfa / Enzyme replacement therapy / ERT / Amyotrophic lateral sclerosis / Immunogenicity / Medicine / Health / Rare diseases


October 11, 2012 Amicus Therapeutics Announces Positive Pompe Program Updates AT2220-Enzyme Replacement Therapy (ERT) Co-Administration Increases Pompe Enzyme (rhGAA) Activity in First 3 Dose Cohorts in Phase 2 Study AT
Add to Reading List

Document Date: 2012-11-15 18:10:29

Open Document

File Size: 103,46 KB

Share Result on Facebook

City

CRANBURY / PERTH / /

Company

Amicus Therapeutics / Antitope Ltd. / /

Country

Australia / /

Event

FDA Phase / /

IndustryTerm

biopharmaceutical / therapies for rare diseases / study protocol / dose / /

MedicalCondition

rare diseases / disease / lysosomal storage disorders / Fabry disease / human genetic diseases / lysosomal storage disease / respiratory insufficiency / deficiency / Pompe disease / progressive skeletal muscle weakness / /

MedicalTreatment

Enzyme Replacement Therapy / /

Organization

Congress / Muscular Dystrophy Association / /

Person

E.R. Sjoberg / David J. Lockhart / D. J. Lockhart / Pol F. Boudes / K. J. Valenzano / P. Boudes / /

Position

Chief Scientific Officer / Chief Medical Officer / /

Product

Herceptin / AT2220 / EpiScreen / Myozyme / Avastin / Lumizyme / AT2220-ERT / AT2220-Enzyme / /

ProvinceOrState

New Jersey / /

PublishedMedium

PLoS ONE / /

Technology

Pharmacokinetics / study protocol / antibodies / /

URL

www.pompestudy.com / www.clinicaltrials.gov / /

SocialTag